Aesica has launched a new facility at their Queenborough site which will focus on formulation development and clinical manufacture. The new Development Centre will encompass all supporting analytical services and the capacity for stability testing. Additionally, the new Centre more than doubles Aesica’s capacity for formulation development and clinical manufacture, which will in turn provide greater flexibility when developing products.
The new facility is based at the Queenborough Manufacturing Site which is on the Isle of Sheppey in Swale, so as to create a smooth process where products can move easily through development, clinical and commercialisation stages.
Ian Muir, Managing Director of Aesica Pharmaceuticals commented:
“In response to growing customer demand, and as part of our on-going strategy to meet the needs of the market to simplify the supply chain with reliable, highly efficient, single source solutions, we have taken the strategic initiative to ensure that our high capacity Queenborough Development Centre, which doubles our development capacity, combined with our commercial manufacturing capabilities at the facility, provides a complete service offering for formulation, development and product manufacturing for multiple customers.”
For further information about the Development Centre please contact Aesica on: